Presentation is loading. Please wait.

Presentation is loading. Please wait.

Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-small Cell Lung Cancer: A Meta-Analysis Based.

Published by徒 薛 Modified over 5 years ago

Similar presentations

Presentation on theme: "Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-small Cell Lung Cancer: A Meta-Analysis Based."— Presentation transcript:

1 Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-small Cell Lung Cancer: A Meta-Analysis Based on Updated Individual Patient Data from Six Medical Centers in Mainland China  Yi-Long Wu, MD, Wen-Zhao Zhong, MD, Long-Yun Li, MD, Xiao-Tong Zhang, MD, Li Zhang, MD, Cai-Cun Zhou, MD, Wei Liu, MD, Bin Jiang, MD, Xin-Lin Mu, MD, Jia-Ying Lin, PhD, Qing Zhou, PhD, Chong-Rui Xu, PhD, Zhen Wang, PhD, Guo-Chun Zhang, PhD, Tony Mok, MD  Journal of Thoracic Oncology  Volume 2, Issue 5, Pages (May 2007) DOI: /01.JTO c Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Relationship between EGFR mutations and the patient characteristics. A, Patients with adenocarcinoma had a significantly higher EGFR mutation rate (44.1%) than those without adenocarcinoma (9.2%). The pooled IPD Peto OR and 95% CI was 5.41 ( ) (p < ). B, Men had a lower EGFR mutation rate (23.1%) than women (42.9%), with the Peto OR and 95% CI being 0.42 (0.28–0.63) (p < ). C, Smokers had a lower EGFR mutation rate (15.1%) than non-smokers (45.5%), with the Peto OR and 95% CI being 0.24 (016–0.36) (p < ). Journal of Thoracic Oncology 2007 2, DOI: ( /01.JTO c) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Relationship between EGFR mutations and response to gefitinib. A, The response rate in EGFR mutation group (60.7%, 17 of 28) was significantly higher than that of EGFR wild-type group (17.2%, 5 of 29). The IPD Peto OR and 95% CI was 5.78 (1.95–17.13) (p = 0.002). B, The overall response rate to gefitinib was 38.6 % (22 of 57); the EGFR mutation rate was % (28 of 57) in this subset. The subgroup analyses showed that response rate favored all the following six combinations with the overall effect Z value and p values as follows: F+A (Z = 2.65, p = 0.008), NS+F (Z = 2.77, p = 0.006), A+NS (Z = 3.52, p = ), A+NS+F (Z = 2.94, p = 0.003), A+NS+EM (Z = 3.97, p < ), and EM+A+NS+F (Z = 3.14, p = 0.002). Journal of Thoracic Oncology 2007 2, DOI: ( /01.JTO c) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Kaplan-Meier plot of overall survival derived from IPD of GDPPH and PKUMCH. Data are grouped by exon mutation sites. Journal of Thoracic Oncology 2007 2, DOI: ( /01.JTO c) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-small Cell Lung Cancer: A Meta-Analysis Based."

Similar presentations

Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 

Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 
Volume 79, Issue 1, Pages (January 2013)

Volume 79, Issue 1, Pages (January 2013)
Society of Thoracic Surgeons 2008 cardiac risk models predict in-hospital mortality of heart valve surgery in a Chinese population: A multicenter study 

Society of Thoracic Surgeons 2008 cardiac risk models predict in-hospital mortality of heart valve surgery in a Chinese population: A multicenter study 
High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules  Chunyan Wu, MD, Chao Zhao, MD, Yang Yang,

High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules  Chunyan Wu, MD, Chao Zhao, MD, Yang Yang,
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,
Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S

Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S
Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,
A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R 

A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R 
Outcomes of per-oral endoscopic myotomy for treatment of esophageal achalasia with a median follow-up of 49 months  Quan-Lin Li, MD, Qiu-Ning Wu, MD,

Outcomes of per-oral endoscopic myotomy for treatment of esophageal achalasia with a median follow-up of 49 months  Quan-Lin Li, MD, Qiu-Ning Wu, MD,
Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations

Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations
SC17.02 Lung Cancer in China: Challenges and Perspectives

SC17.02 Lung Cancer in China: Challenges and Perspectives
Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas  Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas  Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.
Volume 74, Issue 6, Pages (December 2018)

Volume 74, Issue 6, Pages (December 2018)
Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,
Diagnostic Performance of Integrated Positron Emission Tomography/Computed Tomography for Mediastinal Lymph Node Staging in Non-small Cell Lung Cancer:

Diagnostic Performance of Integrated Positron Emission Tomography/Computed Tomography for Mediastinal Lymph Node Staging in Non-small Cell Lung Cancer:
Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.
The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC  Si-Yang Liu, MD, Lan-Ying Gou, MD, An-Na Li, MD, Na-Na Lou, MMed, Hong-Fei.

The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC  Si-Yang Liu, MD, Lan-Ying Gou, MD, An-Na Li, MD, Na-Na Lou, MMed, Hong-Fei.
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Similar presentations

Ads by Google